

# IDF-11774

Catalog No: tcsc0040309



## Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 50mg



## Specifications

### CAS No:

1429054-28-3

### Formula:

$C_{23}H_{32}N_2O_2$

### Pathway:

Metabolic Enzyme/Protease

### Target:

HIF/HIF Prolyl-Hydroxylase

### Purity / Grade:

>98%

### Solubility:

DMSO : 60 mg/mL (162.82 mM; Need ultrasonic and warming)

### Observed Molecular Weight:

368.51

## Product Description


IDF-11774 is a novel **hypoxia-inducible factor (HIF)-1** inhibitor with an **IC<sub>50</sub>** of 3.65 μM. IDF-11774 has been approved as a clinical

candidate for a phase I study.

IC50 & Target: IC50: 3.65  $\mu$ M (HIF-1)<sup>[1]</sup>

**In Vitro:** IDF-11774 is a novel hypoxia-inducible factor (HIF)-1 inhibitor with an IC<sub>50</sub> of 3.65  $\mu$ M in cancer cell line. IDF-11774 has been approved as a clinical candidate for a phase I study. Human umbilical vascular endothelial cells (HUVECs) treated with IDF-11774 show reduced capillary network formation on Matrigel. IDF-11774 treatment leads to reduced mRNA expression of GLUT1 and pyruvate dehydrogenase kinase 1 (PDK1). In addition, intracellular ATP levels are significantly reduced in the presence of IDF-11774 and are affected to a greater degree under low glucose conditions (5.5 mM)<sup>[1]</sup>.

**In Vivo:** Luciferase activity and HIF-1 $\alpha$  accumulation are strongly suppressed in the tumors of mice treated by oral administration of IDF-11774, compare with the control. When IDF-11774 is orally administered daily for two weeks, significant dose-dependent tumor regression is observed in the mouse model<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!